Enterprise Value
-1.745B
Cash
3.558B
Avg Qtr Burn
-108.4M
Short % of Float
3.60%
Insider Ownership
0.00%
Institutional Own.
31.93%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Jyseleca (Filgotinib) Details Ulcerative colitis | Approved Quarterly sales | |
Filgotinib Details Axial spondyloarthritis | Phase 3 Data readout | |
Filgotinib Details Crohns disease | Phase 3 Update | |
GLPG3667 Details Dermatomyositis | Phase 2 Data readout | |
GLPG3667 Details Systemic lupus erythematosus | Phase 2 Data readout | |
GLPG2737 (CFTR inhibitor) Details Autosomal Dominant Polycystic Kidney Disease | Phase 2 Data readout | |
GLPG5101 (CD19 CAR-T) Details Non-Hodgkin lymphoma, Cancer | Phase 1/2 Data readout | |
GLPG5201 (CD19 CAR-T) Details Chronic lymphocytic leukemia, Small lymphocytic lymphoma | Phase 1/2 Data readout | |
GLPG5301 BCMA CAR-T Details Multiple myeloma, High Refractory Multiple Myeloma | Phase 1/2 Data readout | |
Ziritaxestat (GLPG1690) Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
GLPG4716 (CHIT1/AMCase inhibitor) Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
GLPG1205 (GPR84 inhibitor) Details Idiopathic pulmonary fibrosis | Failed Discontinued | |
GLPG3970 (SIK2/3 inhibitor) Details Psoriasis, Rheumatoid arthritis, Ulcerative colitis, Systemic lupus erythematosus | Failed Discontinued | |
GLPG5101 (CD19 CAR-T) Details Systemic lupus erythematosus, Autoimmune disease | Failed Discontinued |